Dolev Rafaeli - STRATA Skin CEO President

SSKN Stock  USD 2.68  0.02  0.75%   

CEO

Dr. Dolev Rafaeli was appointed as an Interim Chief Executive Officer of the Company, with effect from April 10, 2018 since 2018.
Age 61
Tenure 7 years
Address 5 Walnut Grove Drive, Horsham, PA, United States, 19044
Phone215 619 3200
Webhttps://www.strataskinsciences.com
Dolev Rafaeli has over 25 years of experience in the healthcare, medical device, consumer and industrial services fields. He served as a Member of the Board of Directors of the company that founded the XTRAC, PhotoMedex, since 2011 and was its CEO from 2006 to 2015. Under his management at PhotoMedex, he oversaw sales growth from $19 million to over $300 million, driven by increases in brand portfolio, distribution channels and M&A transactions. He was President and CEO of Radiancy, a subsidiary of PhotoMedex, from 2006 to 2017.

Dolev Rafaeli Latest Insider Activity

Tracking and analyzing the buying and selling activities of Dolev Rafaeli against STRATA Skin stock is an integral part of due diligence when investing in STRATA Skin. Dolev Rafaeli insider activity provides valuable insight into whether STRATA Skin is net buyers or sellers over its current business cycle. Note, STRATA Skin insiders must abide by specific rules, including filing SEC forms every time they buy or sell STRATA Skin'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

STRATA Skin Management Efficiency

The company has return on total asset (ROA) of (0.0885) % which means that it has lost $0.0885 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7349) %, meaning that it created substantial loss on money invested by shareholders. STRATA Skin's management efficiency ratios could be used to measure how well STRATA Skin manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of March 2025, Return On Tangible Assets is likely to drop to -0.36. In addition to that, Return On Capital Employed is likely to drop to -0.35. At this time, STRATA Skin's Non Current Assets Total are very stable compared to the past year. As of the 22nd of March 2025, Non Currrent Assets Other is likely to grow to about 304.8 K, while Total Assets are likely to drop about 30.1 M.
STRATA Skin Sciences currently holds 15.63 M in liabilities with Debt to Equity (D/E) ratio of 0.35, which is about average as compared to similar companies. STRATA Skin Sciences has a current ratio of 1.27, suggesting that it may have difficulties to pay its financial obligations when due. Note, when we think about STRATA Skin's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 9 records

CEO Age

Nicholas CurtisLENSAR Inc
69
Gary MaharajSurModics
62
Nadim YaredCVRx Inc
56
Karen ZaderejAxogen Inc
63
Joel BeckerNeuropace
57
Massimo CalafioreOrthofix Medical
52
Mark WhiteNexalin Technology
64
Kevin HykesCVRx Inc
59
Kathleen SkarvanElectromed
68
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania. Strata Skin operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 115 people. STRATA Skin Sciences (SSKN) is traded on NASDAQ Exchange in USA. It is located in 5 Walnut Grove Drive, Horsham, PA, United States, 19044 and employs 99 people. STRATA Skin is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

STRATA Skin Sciences Leadership Team

Elected by the shareholders, the STRATA Skin's board of directors comprises two types of representatives: STRATA Skin inside directors who are chosen from within the company, and outside directors, selected externally and held independent of STRATA. The board's role is to monitor STRATA Skin's management team and ensure that shareholders' interests are well served. STRATA Skin's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, STRATA Skin's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dolev Rafaeli, CEO President
Shmuel Gov, Chief Officer
John Gillings, Principal Officer
Robert Moccia, CEO Pres
William MBA, Ex Chairman
Michael Stewart, CEO and President and Director
Michael Goodman, Head Sales
Darrell Rigel, Chief Advisor
Keith Simeone, VP Sales
Nikolai Kabelev, VP RD
Christopher Lesovitz, Chief Officer
Jay Sturm, General Secretary

STRATA Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is STRATA Skin a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
When determining whether STRATA Skin Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of STRATA Skin's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Strata Skin Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Strata Skin Sciences Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in STRATA Skin Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of STRATA Skin. If investors know STRATA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about STRATA Skin listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.60)
Revenue Per Share
8.978
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.09)
Return On Equity
(0.73)
The market value of STRATA Skin Sciences is measured differently than its book value, which is the value of STRATA that is recorded on the company's balance sheet. Investors also form their own opinion of STRATA Skin's value that differs from its market value or its book value, called intrinsic value, which is STRATA Skin's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because STRATA Skin's market value can be influenced by many factors that don't directly affect STRATA Skin's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between STRATA Skin's value and its price as these two are different measures arrived at by different means. Investors typically determine if STRATA Skin is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, STRATA Skin's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.